{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T05:02:15Z","timestamp":1698728535309},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s11892-009-0004-y","type":"journal-article","created":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T13:05:29Z","timestamp":1233666329000},"page":"11-17","source":"Crossref","is-referenced-by-count":15,"title":["Managing diabetic dyslipidemia: Beyond statin therapy"],"prefix":"10.1007","volume":"9","author":[{"given":"Hemanth","family":"Neeli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Gadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,4]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J. Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk-factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434\u2013444.","journal-title":"Diabetes Care"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/diacare.21.1.69","volume":"21","author":"H. Miettinen","year":"1998","unstructured":"Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998, 21:69\u201375.","journal-title":"Diabetes Care"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"C.P. Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495\u20131504.","journal-title":"N Engl J Med"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"J.C. LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425\u20131435.","journal-title":"N Engl J Med"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","volume":"292","author":"J.A. Lemos de","year":"2004","unstructured":"de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307\u20131316.","journal-title":"JAMA"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0021-9150(85)90003-6","volume":"56","author":"M. Laakso","year":"1985","unstructured":"Laakso M, Voutilainen E, Sarlund H, et al.: Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 1985, 56:271\u2013281.","journal-title":"Atherosclerosis"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1161\/01.ATV.12.12.1496","volume":"12","author":"K.R. Feingold","year":"1992","unstructured":"Feingold KR, Grunfeld C, Pang M, et al.: LDL subclass phenotypes and triglyceride-metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992, 12:1496\u20131502.","journal-title":"Arterioscler Thromb"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","volume":"46","author":"M.R. Taskinen","year":"2003","unstructured":"Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733\u2013749.","journal-title":"Diabetologia"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00145359","volume":"8","author":"G. Assmann","year":"1992","unstructured":"Assmann G, Schulte H: The importance of triglycerides: results from the Prospective Cardiovascular M\u00fcnster (ProcAM) Study. Eur J Epidemiol 1992, 8:99\u2013103.","journal-title":"Eur J Epidemiol"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1001\/jama.1990.03440210043030","volume":"263","author":"S.M. Haffner","year":"1990","unstructured":"Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk-factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893\u20132898.","journal-title":"JAMA"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(03)00239-9","volume":"173","author":"R.S. Rosenson","year":"2004","unstructured":"Rosenson RS: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004, 173:1\u201312.","journal-title":"Atherosclerosis"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1055\/s-2001-18580","volume":"109","author":"M.R. Taskinen","year":"2001","unstructured":"Taskinen MR: Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001, 109:S180\u2013S188.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI111711","volume":"75","author":"C.S. Wang","year":"1985","unstructured":"Wang CS, McConathy WJ, Kloer HU, Alaupovic P: Modulation of lipoprotein-lipase activity by apolipoproteins. Effect of apolipoprotein-C-III. J Clin Invest 1985, 75:384\u2013390.","journal-title":"J Clin Invest"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1016\/S0021-9258(18)55263-7","volume":"266","author":"E. Sehayek","year":"1991","unstructured":"Sehayek E, Eisenberg S: Mechanisms of inhibition by apolipoprotein C of apolipoprotein-E-dependent cellular-metabolism of human triglyceride-rich lipoproteins through the low-density-lipoprotein receptor pathway. J Biol Chem 1991, 266:18259\u201318267.","journal-title":"J Biol Chem"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1056-8727(01)00191-X","volume":"16","author":"S. Rashid","year":"2002","unstructured":"Rashid S, Uffelman KD, Lewis GF: The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002, 16:24\u201328.","journal-title":"J Diabetes Complications"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1021\/bi9919504","volume":"39","author":"S. Braschi","year":"2000","unstructured":"Braschi S, Neville TA, Maugeais C, et al.: Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. Biochemistry 2000, 39:5441\u20135449.","journal-title":"Biochemistry"},{"key":"4_CR17","doi-asserted-by":"crossref","unstructured":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486\u20132589.","DOI":"10.1001\/jama.285.19.2486"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)12475-0","volume":"361","author":"R. Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, et al.: MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005\u20132016.","journal-title":"Lancet"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"S.M. Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227\u2013239.","journal-title":"Circulation"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"H.M. Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685\u2013696.","journal-title":"Lancet"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","volume":"20","author":"K. Pyorala","year":"1997","unstructured":"Pyorala K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614\u2013620.","journal-title":"Diabetes Care"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","volume":"98","author":"R.B. Goldberg","year":"1998","unstructured":"Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513\u20132519.","journal-title":"Circulation"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","volume":"26","author":"A. Keech","year":"2003","unstructured":"Keech A, Colquhoun D, Best J, et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713\u20132721.","journal-title":"Diabetes Care"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C. Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267\u20131278.","journal-title":"Lancet"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/01.CIR.0000012918.84068.43","volume":"105","author":"F.M. Sacks","year":"2002","unstructured":"Sacks FM, Tonkin AM, Craven T, et al.: Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002, 105:1424\u20131428.","journal-title":"Circulation"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2165\/00003495-200262130-00013","volume":"62","author":"G.M. Keating","year":"2002","unstructured":"Keating GM, Ormrod D: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002, 62:1909\u20131944.","journal-title":"Drugs"},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"H.B. Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410\u2013418.","journal-title":"N Engl J Med"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"M.H. Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237\u20131245.","journal-title":"N Engl J Med"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","volume":"45","author":"R.S. Birjmohun","year":"2005","unstructured":"Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185\u2013197.","journal-title":"J Am Coll Cardiol"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2337\/diacare.15.7.820","volume":"15","author":"P. Koskinen","year":"1992","unstructured":"Koskinen P, Manttari M, Manninen V, et al.: Coronary heart-disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820\u2013825.","journal-title":"Diabetes Care"},{"key":"4_CR31","doi-asserted-by":"crossref","unstructured":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study [no authors listed]. Circulation 2000, 102:21\u201327.","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","volume":"357","author":"G. Steiner","year":"2001","unstructured":"Steiner G, Hamsten A, Hosking J, et al.: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905\u2013910.","journal-title":"Lancet"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A. Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849\u20131861.","journal-title":"Lancet"},{"issue":"12A","key":"4_CR34","doi-asserted-by":"crossref","first-page":"56i","DOI":"10.1016\/j.amjcard.2007.03.024","volume":"99","author":"H.N. Ginsberg","year":"2007","unstructured":"Ginsberg HN, Bonds DE, Lovato LC, et al.: Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99(12A):56i\u201367i.","journal-title":"Am J Cardiol"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/med.20102","volume":"27","author":"W. Soudijn","year":"2007","unstructured":"Soudijn W, van Wijngaarden I, Ijzerman AP: Nicotinic acid receptor subtypes and their ligands. Med Res Rev 2007, 27:417\u2013433.","journal-title":"Med Res Rev"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.17.10.2020","volume":"17","author":"F.Y. Jin","year":"1997","unstructured":"Jin FY, Kamanna VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997, 17:2020\u20132028.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4_CR37","doi-asserted-by":"crossref","unstructured":"Clofibrate and niacin in coronary heart disease [no authors listed]. JAMA 1975, 231:360\u2013381.","DOI":"10.1001\/jama.1975.03240160024021"},{"key":"4_CR38","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"P.L. Canner","year":"1986","unstructured":"Canner PL, Berge KG, Wenger NK, et al.: 15-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245\u20131255.","journal-title":"J Am Coll Cardiol"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","volume":"345","author":"B.G. Brown","year":"2001","unstructured":"Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583\u20131592.","journal-title":"N Engl J Med"},{"key":"4_CR40","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","volume":"22","author":"A.J. Taylor","year":"2006","unstructured":"Taylor AJ, Lee HJ, Sullenberger LE: The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006, 22:2243\u20132250.","journal-title":"Curr Med Res Opin"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1172\/JCI10762","volume":"106","author":"H.N. Ginsberg","year":"2000","unstructured":"Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453\u2013458.","journal-title":"J Clin Invest"},{"key":"4_CR42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1056-8727(97)00053-6","volume":"12","author":"P.J. Palumbo","year":"1998","unstructured":"Palumbo PJ: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998, 12:110\u2013119.","journal-title":"J Diabetes Complications"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"J.A. Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279\u20131289.","journal-title":"Lancet"},{"key":"4_CR44","first-page":"A324","volume":"51","author":"M.J. Koren","year":"2008","unstructured":"Koren MJ, Maccubbin D, Davidson M, et al.: Flushing profile of extended release niacin\/laropiprant versus gradually titrated Niaspan in patients with dyslipidemia. J Am Coll Cardiol 2008, 51:A324\u2013A325.","journal-title":"J Am Coll Cardiol"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.amjcard.2005.01.073","volume":"95","author":"G.L. Vega","year":"2005","unstructured":"Vega GL, Cater NB, Meguro S, Grundy SM: Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005, 95:1309\u20131313.","journal-title":"Am J Cardiol"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.amjcard.2006.08.044","volume":"99","author":"A.A. Alsheikh-Ali","year":"2007","unstructured":"Alsheikh-Ali AA, Karas RH: Safety of lovastatin\/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007, 99:379\u2013381.","journal-title":"Am J Cardiol"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-009-0004-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0004-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:54:36Z","timestamp":1633049676000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-009-0004-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11892-009-0004-y","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}